Khatri 2018.

Study characteristics
Methods	Double blind Step forward randomisation procedure, ratio of 1:1 Losses to follow‐up: 22%
Participants	Acute ischaemic stroke with deficits not clearly disabling at presentation 313 participants 54% male Aspirin group: 157; 92 male, 65 female; mean age: 61 (SD 13) years Placebo group: 156; 77 male, 79 female; mean age: 61 (SD 14) years Duration: 90 days
Interventions	Treatment: oral aspirin 325 mg + IV placebo Control: oral placebo + IV alteplase
Outcomes	Primary outcomes mRS score 0–6 (at day 90) NIHSS score Secondary outcomes Level of disability (mRS score) Global favourable recovery (mRS score 0 or 1) NIHSS score 0 or 1 BI 95 or 100 Glasgow outcome scale of 1
Funding source	No comment on source of funding available.
Notes	Study terminated early.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Step‐forward randomisation procedure used.
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement.
Blinding of participants and personnel (performance bias) all outcomes	Low risk	Blinding of participants and personnel.
Blinding of outcome assessment (detection bias) all outcomes	Unclear risk	Only reported CT scans as blinded, not other outcomes.
Incomplete outcome data (attrition bias) all outcomes	Low risk	Missing outcome data was imputed via hot‐deck method.
Selective reporting (reporting bias)	Low risk	Study protocol available.
Other bias	Low risk	No sources of other bias identified.